NCT07104565View on ClinicalTrials.gov

Study to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell Disorders

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

56

Participants

Timeline

Start Date

October 15, 2025

Primary Completion Date

September 23, 2027

Study Completion Date

March 9, 2028

Conditions

Immune Thrombocytopenia

Interventions

DRUG

INCA000585

Tafasitamab will be administered intravenously at protocol defined timepoints.

Sponsors

Lead Sponsor

Incyte Corporation

All Listed Sponsors

lead

Incyte Corporation

INDUSTRY